Key Takeaways
- BSX shares hit a 52-week bottom at $60.54, representing approximately a 36% decline since the start of 2026
- Stifel reduced its price objective from $90 down to $85 based on electrophysiology purchasing trends before Q1 2026 results
- The company reports first-quarter 2026 financials on April 22, 2026
- Wall Street analysts continue to recommend Buy/Outperform positions despite reduced price objectives — RBC maintains a $115 forecast, UBS stays at $105
- InvestingPro identifies BSX among its Most Undervalued selections with a Fair Value assessment of $76.66
Shares of Boston Scientific have experienced significant turbulence throughout 2026. The medical device manufacturer saw BSX plummet to a 52-week bottom of $60.54 on April 21, with shares currently hovering between $60.43 and $60.99 — a dramatic departure from the 52-week peak of $109.50.
Boston Scientific Corporation, BSX
This represents approximately a 36% year-to-date collapse, wiping out substantial value from the company’s $90.6 billion market capitalization.
Rick Wise, an analyst at Stifel, trimmed his price objective on BSX to $85 from the previous $90 in anticipation of the first-quarter 2026 financial report, scheduled for release on April 22, 2026. His Buy recommendation remains intact.
The adjustment stems from monthly electrophysiology (EP) hospital procurement statistics that Stifel monitors to gauge quarterly performance ahead of official announcements.
January figures showed approximately 92% completion, February reached around 85%, and March stood at roughly 60% — offering an incomplete yet significant snapshot of EP sales momentum.
According to this dataset, Stifel projects BSX’s Q1 domestic EP consensus revenue forecast of approximately $587 million falls “within the band of achievability.” While not enthusiastically optimistic, it stops short of sounding alarm bells.
Stifel referenced comparisons with Johnson & Johnson and Abbott Laboratories, utilizing the identical EP procurement database to validate projected against actual revenue figures. The firm had earlier identified possible downside exposure to US EP consensus revenues before the previous quarter through comparable analysis.
Wall Street Price Objectives Remain Above Trading Levels
Notwithstanding the negative market sentiment, Wall Street analysts haven’t entirely retreated. Truist Securities maintained its Buy stance while adjusting its target downward to $90 from $92. The firm anticipates the cardiovascular division will expand 8.5% to 9% in the forthcoming announcement.
RBC Capital reaffirmed an Outperform position with a $115 price objective following direct conversations with BSX management regarding expansion opportunities.
UBS retained its Buy recommendation and $105 forecast after reviewing CHAMPION-AF clinical trial data for the Watchman cardiac implant. The study achieved all primary and secondary benchmarks — a favorable result that UBS believes diminishes headline exposure.
However, there’s a complication. The Watchman technology demonstrated a marginally elevated ischemic stroke incidence relative to non-vitamin K antagonist oral anticoagulants (NOACs), which let down certain market participants.
Piper Sandler preserved its Overweight designation following input from a high-volume electrophysiologist who anticipates increased Watchman adoption notwithstanding the stroke statistics.
Shares Identified as Trading Below Value
InvestingPro has designated BSX among its most undervalued securities, establishing its Fair Value at $76.66 — approximately 27% higher than current trading levels.
Revenue expansion has stayed robust, with BSX delivering nearly 20% growth throughout the trailing twelve months. On fundamentals alone, this isn’t a deteriorating enterprise — it’s equity under market pressure.
Attention now shifts to April 22, when BSX unveils Q1 2026 financial results. That announcement will serve as the initial genuine validation of whether EP revenue maintained strength as Stifel’s information indicates it potentially did.
